Major Depression Clinical Trial
Official title:
The Brain on Whole Body Hyperthermia: A Neuroimaging Study
The investigators have observed in an open trial that a single session of whole body hyperthermia (WBH) induced rapid antidepressant effects that persisted for at least a week in patients with major depression (MDD) severe enough to warrant inpatient hospitalization. In addition to reducing depression, the single session of WBH induced a prolonged reduction in mean core body temperature, consistent with basic science data from our group suggesting that hyperthermia activates a skin-to-brain pathway that have been shown in animals to be important for mood and body temperature regulation. Consistent with this known anatomy in our preliminary study in depressed patients, reductions in core body temperature were highly correlated with reductions in depressive symptoms over the same time period (one week post WBH). Moreover, patients with higher mean core body temperature prior to treatment had enhanced antidepressant effects. Because increased body temperature is an outcome of poor functioning in the skin-to-brain pathway activated by WBH our data suggests that WBH may actually sensitize this pathway in ways that promote changes in brain functioning known to promote emotional well-being. The results of our first open trial have encouraged us to conduct a larger, more rigorous placebo-controlled, double blind study of WBH for MDD, which is currently underway at the University of Arizona Medical School. Missing from our assessments in this ongoing double-blind study is any measure of the impact of WBH on brain function. The current proposal addresses ths gap in our investigative portfolio by proposing to conduct a second, randomized trial of active vs. sham WBH that will examine the impact of WBH on measures of brain function known from prior studies to be important for both depression and its treatment.
The Investigators have observed in an open trial that a single session of whole body
hyperthermia (WBH) induced rapid antidepressant effects that persisted for at least a week
in patients with major depression (MDD) severe enough to warrant inpatient hospitalization.
In addition to reducing depression, the single session of WBH induced a prolonged reduction
in mean core body temperature, consistent with basic science data from our group suggesting
that hyperthermia activates a skin-to-brain pathway that targets specific serotonergic
nuclei in the raphe. In animal models, these nuclei have been shown to be important for mood
and body temperature regultion. Consistent with this known anatomy in our preliminary study
in depressed patients, reductions in core body temperature were highly correlated with
reductions in depressive symptoms over the same time period (one week post WBH). Moreover,
patients with higher mean core body temperature prior to treatment had enhanced
antidepressant effects. Because increased body temperature is an outcome of poor functioning
in the skin-to-brain pathway activated by WBH our data suggest that WBH may actually
sensitize this pathway in ways that promote changes in brain functioning known to promote
emotional well-being. The results of our first open trial have encouraged us to conduct a
larger, more rigorous placebo-controlled, double blind study of WBH for MDD, which is
currently underway at the University of Arizona Medical School. In addition to assessing
effects on depressive symptoms in comparison to a sham condition, this study examines the
effect of WBH on body temperature, autonomic nervous system function, thermoregulatory
cooling, immune, neuroendocrine and monoamine functioning and real-world daily social
behavior.
Missing from our assessments in this ongoing double-blind study is any measure of the impact
of WBH on brain function. The current proposal addresses ths gap in our investigative
portfolio by proposing to conduct a second, randomized trial of active vs. sham WBH that
will examine the impact of WBH on measures of brain function known from prior studies to be
important for both depression and its treatment. These measures will include functional
magnetic resonance imaging (fMRI) analyses of resting state brain connectivity as well as
assessments of concordance between subgenual anterior cingulate cortex and autonomic nervous
system function assessed by electrocardiogram (EKG). Prior to these fMRI assessments a
structural MRI will be obtained.
The investigators propose to conduct this fMRI/EKGtudy in 30 students (15 males/15 females)
recruited from the PSYC150A1 Mass survey, which allows University of Arizona students an
opportunity to serve as research subjects for course credit. These potential participants
will be between the ages of 18 and 30 and will have self-reported depressive symptomatology
of at least moderate severity, as reflected in a Beck Depression Inventory (BDI) II score ≥
14. Participants will be medically healthy with no history of bipolar I disorder,
schizophrenia or active substance dependence. Participants will complete questionnaires one
week prior to, the day of, and one week following a single administration of either WBH or
sham WBH (delivered with a 1-to-1 ratio). On the morning prior receiving WBH or sham WBH and
again 24 hours later all subjects will undergo fMRI/EKG assessment. This design will allow
us to evaluate the acute brain effects of WBH and to evaluate the relationship between these
changes and both acute and short term (i.e. one week post treatment) improvements in mood.
;
Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT03062150 -
Mineralocorticoid Receptor, NMDA Receptor and Cognitive Function in Depression
|
N/A | |
Completed |
NCT04352101 -
Bupropion Versus Escitalopram on Reward Circuitry and Motivational Deficits
|
Phase 4 | |
Completed |
NCT02855918 -
Blood Biomarkers in Suicidal Behaviour
|
N/A | |
Recruiting |
NCT03039387 -
Effects of tDCS on Cognitive Control and Emotion Regulation in Depressed Patients
|
N/A | |
Recruiting |
NCT02213016 -
Effectiveness of Repetitive Transcranial Magnetic Stimulation in Depressed Patients
|
Phase 4 | |
Completed |
NCT01683539 -
Understanding How Cognitive Remediation Works
|
N/A | |
Completed |
NCT01636791 -
CBT Versus a Return to Work Intervention for Patients With Common Mental Illness in Primary Care
|
Phase 3 | |
Recruiting |
NCT02237937 -
Optimizing Antidepressant Treatment by Genotype-dependent Adjustment of Medication According to the ABCB1 Gene
|
Phase 4 | |
Completed |
NCT01201148 -
Open Pilot Trial of TES for Depression
|
Phase 2 | |
Completed |
NCT00953108 -
Quetiapine Prolong, Escitalopram and Hypothalamic-pituitary-adrenocortical (HPA) Axis Activity in Depressed Patients
|
Phase 3 | |
Completed |
NCT00711737 -
Study of the Changes in Metabolic Parameters in Patients Treated With Escitalopram for Six Months
|
N/A | |
Completed |
NCT00806143 -
Bilateral Versus Monolateral Repetitive Transcranial Stimulation in Depression
|
Phase 4 | |
Terminated |
NCT00695552 -
The Effect of Exercise on Depressive Symptoms in Unmedicated Patients
|
N/A | |
Terminated |
NCT01244711 -
Open-Label Pilot Study to Examine the Value of Substituting Quetiapine for Benzodiazepines
|
Phase 4 | |
Completed |
NCT00466323 -
The Effectiveness of FMPO in Improving the Quality of Care for Persons With Severe Mental Illness.
|
N/A | |
Completed |
NCT00532480 -
Study of Brain Response to Emotional Pictures Using a fMRI While on Duloxetine
|
Phase 4 | |
Completed |
NCT00482482 -
Yoga in Unipolar and Bipolar Disorders
|
N/A | |
Completed |
NCT00616759 -
The Effect on Cognition of Terminating ECT Induced Seizures With Propofol
|
N/A | |
Recruiting |
NCT00209807 -
Effect of Escitalopram vs. Reboxetine on Gastro-intestinal Sensitivity of Patients With Major Depressive Disorder
|
Phase 4 | |
Completed |
NCT00167310 -
Decreasing Risk of Coronary Artery Disease in Schizophrenia by Omega-3 Fatty Acid Supplementation
|
Phase 2 |